Accumulating evidence has demonstrated the abnormal expression of ZFAS1 in multiple cancers, including gastric cancer, hepatocellular carcinoma, colorectal cancer, glioma, osteosarcoma, ovarian cancer, acute myeloid leukaemia, NSCLC, oesophageal squamous cell carcinoma, and breast cancer. Here, ZFAS1 is linked to central nervous system cancer.